Nafithromycin: advancements in antibiotic therapy against community-acquired pneumonia-resistant pathogens
Abstract
Nafithromycin (WCK 4873) is a novel lactone ketolide antibiotic developed to address the critical issue of multidrug-resistant bacteria, especially those causing community-acquired pneumonia (CAP). Given the increasing prevalence of antibiotic resistance, there is a pressing need for new antibiotics with improved efficacy and safety profiles. This review synthesizes data from various in vitro studies and clinical trials to evaluate the pharmacological properties, mechanism of action, and clinical potential of nafithromycin. Key clinical trials assessed the drug's pharmacokinetics, safety, and efficacy in both healthy volunteers and patients with CAP. Nafithromycin exhibits strong in vitro antimicrobial activity against a broad spectrum of pathogens, including macrolide-resistant and telithromycin-insensitive strains. Clinical trials demonstrated that nafithromycin has a favorable pharmacokinetic profile, with high lung tissue concentrations and manageable side effects. Phase I studies confirmed its safety and tolerability in healthy adults, while Phase II trials showed its efficacy in treating CAP, with a 3-day treatment regimen proving comparable to a seven-day regimen of moxifloxacin. Nafithromycin holds significant promise as a therapeutic agent against respiratory infections caused by resistant bacteria. Its unique mechanism of action, high tissue penetration, and broad-spectrum activity position it as a valuable addition to the antimicrobial arsenal. Continued research…
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.